Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22101963 | 0.90 | LMNA (0.45) | LMNAPOLBSMN1; SMN2ACACB | |
| SCHEMBL22101957 | 0.88 | CA12 (0.31) | LMNAPOLB | |
| SCHEMBL22101590 | 0.87 | LMNA (0.31) | LMNAPOLBSMN1; SMN2 | |
| SCHEMBL22101622 | 0.87 | LMNA (0.32) | LMNAPOLBSMN1; SMN2 | |
| SCHEMBL22101989 | 0.87 | ESR1 (0.31) | LMNAPOLB | |
| SCHEMBL22101977 | 0.87 | SMN1; SMN2 (0.40) | LMNAPOLBSMN1; SMN2EPHX2 | |
| SCHEMBL22101774 | 0.87 | LMNA (0.31) | LMNAPOLB | |
| SCHEMBL22101643 | 0.87 | — | — | |
| SCHEMBL22101615 | 0.86 | FPR3 (0.31) | LMNAPOLB | |
| SCHEMBL22101573 | 0.85 | KDM4E (0.32) | POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230172977-A1 | THERAPEUTIC METAL COMPLEXES AND LIGANDS AND METHODS OF MAKING AND USING THE SAME | OREGON STATE UNIVERSITY (US) | 2023-06-08 | — | — | US | disclosed |
| US-20200188430-A1 | THERAPEUTIC METAL COMPLEXES AND LIGANDS AND METHODS OF MAKING AND USING THE SAME | OREGON STATE UNIVERSITY (US) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172977-A1 | THERAPEUTIC METAL COMPLEXES AND LIGANDS AND METHODS OF MAKING AND USING THE SAME | TUFM, SMN1; SMN2, MCU | LMNA 3292/4885POLB 1445/4885SMN1; SMN2 2/4885 |
| US-20200188430-A1 | THERAPEUTIC METAL COMPLEXES AND LIGANDS AND METHODS OF MAKING AND USING THE SAME | TUFM, SMN1; SMN2, MCU | LMNA 3292/4885POLB 1445/4885SMN1; SMN2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.